Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CASP7 | P55210 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Albuterol SCHEMBL5881204 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| (S)-Albuterol SCHEMBL29496690 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Levosalbutamol SCHEMBL29361075 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Albuterol SCHEMBL2489838 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Albuterol SCHEMBL121596 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Levosalbutamol SCHEMBL4003 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Albuterol SCHEMBL10025126 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Albuterol SCHEMBL4913 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Albuterol SCHEMBL122805 | 0.93 | ADRB2 (1.00) | ADRB2HIF1ATSHRADRB1CYP1A2 | |
| Levosalbutamol SCHEMBL18527021 | 0.93 | ADRB2 (0.75) | ADRB2HIF1ATSHRADRB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277669-A1 | USES OF UROLITHINS | AMAZENTIS SA (CH) | 2023-09-07 | — | — | US | disclosed |
| WO-2023161453-A1 | USES OF UROLITHINS | AMAZENTIS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023154746-A2 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LOW FREQUENCY MUTATIONS | THE BROAD INSTITUTE, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230087562-A1 | COMPOSITIONS AND METHODS OF TREATING CARDIAC HYPERTROPHY AND HEART FAILURE | UNIV CASE WESTERN RESERVE (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4138782-A1 | PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PRODUCTS OF HETERODIMERIC HUMAN INTERLEUKIN-15 (HETIL-15) | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20230016609-A1 | MESOPOROUS SILICA NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-19 | — | — | US | disclosed |
| EP-4100425-A1 | CHO CELL EXPRESSING IL-15 HETERODIMERS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115443127-A | Pharmaceutical compositions and products of heterodimers human interleukin-15 (HETIL-15) | 诺华股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-111423417-B | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC医疗公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115023436-A | CHO cells expressing IL-15 heterodimers | 诺华股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20050002934-A1 | Recombinant IL-9 antibodies and uses thereof | MEDIMMUNE, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004108122-A1 | GLYCYRRHIZIN OR DERIVATIVES THEREOF FOR TREATING OR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | JOHANN WOLFGANG GOETHE UNIVERSITY (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091510-A2 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF | MEDIMMUNE, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004091519-A2 | METHODS OF PREVENTING OR TREATING RESPIRATORY CONDITIONS | MEDIMMUNE, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040018200-A1 | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations | MEDIMMUNE, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003105894-A1 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS | MEDIMMUNE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106644-A2 | STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS | MEDIMMUNE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-0605483-B1 | PROPELLANT FOR AEROSOLS AND DOSING AEROSOLS | IG SPRUEHTECHNIK GMBH (DE) | 1996-04-03 | — | — | EP | disclosed |
| EP-0454773-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | Bundgaard, Hans (DK) | 1991-11-06 | — | — | EP | disclosed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087562-A1 | COMPOSITIONS AND METHODS OF TREATING CARDIAC HYPERTROPHY AND HEART FAILURE | NR1H2, FABP3, NR1H3 | ADRB2 46/4885HIF1A 303/4885TSHR 457/4885 |
| US-20230277669-A1 | USES OF UROLITHINS | CD47, CD69, CD44 | ADRB2 3986/4885HIF1A 2980/4885TSHR 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.